This topic contains a solution. Click here to go to the answer

Author Question: A client diagnosed with Parkinson's disease is beginning medication therapy. The nurse realizes that ... (Read 45 times)

ap345

  • Hero Member
  • *****
  • Posts: 537
A client diagnosed with Parkinson's disease is beginning medication therapy. The nurse realizes that the goal of treatment for Parkinson's disease is to:
 
  1. improve sleep.
  2. reduce appetite.
  3. control tremor and rigidity.
  4. reduce the need for joint replacement surgery.

Question 2

A client presents complaining of abnormal muscle weakness and fatigability. The physician suspects myasthenia gravis. Which drug can be used to test for this disease?
 
  1. Pyridostigmine (Mestinon)
  2. Neostigmine (Prostigmin)
  3. Ambenonium (Mytelase)
  4. Edrophonium (Tensilon)



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

EAN94

  • Sr. Member
  • ****
  • Posts: 307
Answer to Question 1

3
The goal of pharmacologic treatment for the client diagnosed with Parkinson's disease is to control tremor and rigidity and to improve the client's ability to carry out the activities of daily living. Medications for Parkinson's disease are not provided to improve sleep, reduce appetite, or reduce the need for joint replacement surgery.

Answer to Question 2

Right on time. Thanks a bunch.




ap345

  • Member
  • Posts: 537
Reply 2 on: Jun 25, 2018
:D TYSM


chjcharjto14

  • Member
  • Posts: 342
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

Bacteria have been found alive in a lake buried one half mile under ice in Antarctica.

Did you know?

The average adult has about 21 square feet of skin.

Did you know?

Essential fatty acids have been shown to be effective against ulcers, asthma, dental cavities, and skin disorders such as acne.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library